In this study, they found that exosomal PD-L1 levels were strongly correlated with tumor PD-L1 levels and worse relapse-free survival in NSCLC patients, suggesting exosomal PD-L1 represents a reliable biomarker to predict anti-PD-1 response and clinical outcomes in patients with NSCLC [26]. The gene discussed is CD274; the disease is neoplasm.